# Case report: Molecular profiling facilitates the diagnosis of a challenging case of lung cancer with choriocarcinoma features

**Authors:** Hui Li, Xin Hu, Matthew S. Ning, Gregory N. Fuller, John M. Stewart, Jared C. Gilliam, Jia Wu, Xiuning Le, Ara A. Vaporciyan, J. Jack Lee, Don L. Gibbons, John V. Heymach, Andrew Futreal, Jianjun Zhang

PMC · DOI: 10.3389/fonc.2024.1324057 · Frontiers in Oncology · 2024-03-25

## TL;DR

Molecular profiling helped diagnose a complex lung cancer case with choriocarcinoma features and guided effective treatment.

## Contribution

This case report demonstrates how molecular profiling can clarify ambiguous cancer diagnoses and inform treatment strategies.

## Key findings

- Molecular profiling identified a KRAS G13R mutation and suggested a lung origin in a complex cancer case.
- Chemoimmunotherapy and consolidation radiation therapy led to no disease progression after 16 months.
- The case highlights the value of genomic and transcriptomic data in challenging cancer diagnoses.

## Abstract

Accurate diagnoses are crucial in determining the most effective treatment across different cancers. In challenging cases, morphology-based traditional pathology methods have important limitations, while molecular profiling can provide valuable information to guide clinical decisions. We present a 35-year female with lung cancer with choriocarcinoma features. Her disease involved the right lower lung, brain, and thoracic lymph nodes. The pathology from brain metastasis was reported as “metastatic choriocarcinoma” (a germ cell tumor) by local pathologists. She initiated carboplatin and etoposide, a regimen for choriocarcinoma. Subsequently, her case was assessed by pathologists from an academic cancer center, who gave the diagnosis of “adenocarcinoma with aberrant expression of β-hCG” and finally pathologists at our hospital, who gave the diagnosis of “poorly differentiated carcinoma with choriocarcinoma features”. Genomic profiling detected a KRAS G13R mutation and transcriptomics profiling was suggestive of lung origin. The patient was treated with carboplatin/paclitaxel/ipilimumab/nivolumab followed by consolidation radiation therapy. She had no evidence of progression to date, 16 months after the initial presentation. The molecular profiling could facilitate diagnosing of challenging cancer cases. In addition, chemoimmunotherapy and local consolidation radiation therapy may provide promising therapeutic options for patients with lung cancer exhibiting choriocarcinoma features.

## Linked entities

- **Genes:** KRAS (KRAS proto-oncogene, GTPase) [NCBI Gene 3845]
- **Chemicals:** carboplatin (PubChem CID 426756), etoposide (PubChem CID 36462), paclitaxel (PubChem CID 36314)
- **Diseases:** lung cancer (MONDO:0005138), choriocarcinoma (MONDO:0003508), adenocarcinoma (MONDO:0004970)

## Full-text entities

- **Genes:** KRAS (KRAS proto-oncogene, GTPase) [NCBI Gene 3845] {aka 'C-K-RAS, C-K-RAS, CFC2, K-RAS2A, K-RAS2B, K-RAS4A}
- **Diseases:** lung cancer (MESH:D008175), poorly differentiated carcinoma (MESH:D020522), cancer (MESH:D009369), germ cell tumor (MESH:D009373), choriocarcinoma (MESH:D002822), adenocarcinoma (MESH:D000230), metastasis (MESH:D009362)
- **Species:** Homo sapiens (human, species) [taxon 9606]
- **Mutations:** G13R

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC10999639/full.md

## Figures

2 figures with captions in the complete paper: https://tomesphere.com/paper/PMC10999639/full.md

## References

51 references — full list in the complete paper: https://tomesphere.com/paper/PMC10999639/full.md

---
Source: https://tomesphere.com/paper/PMC10999639